Michael E. Weinblatt, MD

Michael E. Weinblatt, MD
Co-director of Clinical Rheumatology, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School, Boston, MA

Address: Michael E. Weinblatt, MD, Brigham and Women’s Hospital, Rheumatology-Immunology-Allergy, Arthritis Center, 75 Francis Street, Boston, MA 02115

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

The author has indicated that he has received grant or research support from the Abbott, Amgen, Bristol-Myers Squibb, and Millennium companies and has served as a consultant for Abbott, Amgen, Bristol-Myers Squibb, Centocor, Genentech, Merck, Millennium, Roche, TAP, and Wyeth.

This paper discusses therapies that are investigational or are not approved by the US Food and Drug Administration for the use under discussion.

Michael E. Weinblatt, MD
Co-director of Clinical Rheumatology, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School, Boston, MA

Address: Michael E. Weinblatt, MD, Brigham and Women’s Hospital, Rheumatology-Immunology-Allergy, Arthritis Center, 75 Francis Street, Boston, MA 02115

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

The author has indicated that he has received grant or research support from the Abbott, Amgen, Bristol-Myers Squibb, and Millennium companies and has served as a consultant for Abbott, Amgen, Bristol-Myers Squibb, Centocor, Genentech, Merck, Millennium, Roche, TAP, and Wyeth.

This paper discusses therapies that are investigational or are not approved by the US Food and Drug Administration for the use under discussion.

Michael E. Weinblatt, MD
Co-director of Clinical Rheumatology, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School, Boston, MA

Address: Michael E. Weinblatt, MD, Brigham and Women’s Hospital, Rheumatology-Immunology-Allergy, Arthritis Center, 75 Francis Street, Boston, MA 02115

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

The author has indicated that he has received grant or research support from the Abbott, Amgen, Bristol-Myers Squibb, and Millennium companies and has served as a consultant for Abbott, Amgen, Bristol-Myers Squibb, Centocor, Genentech, Merck, Millennium, Roche, TAP, and Wyeth.

This paper discusses therapies that are investigational or are not approved by the US Food and Drug Administration for the use under discussion.